长春瑞滨联合奥沙利铂对比长春瑞滨联合顺铂治疗中晚期非小细胞肺癌的系统评价

BACKGROUND AND OBJECTIVE: Cisplatin (DDP) plus vinorelbine (NVB) constitute the first-line regimen (NP regimen) for non-small cell lung cancer (NSCLC).Oxaliplatin (OXA) is another effective drug in treatment of NSCLC with mild toxicities to gastrointestinal tract, kidney and bone marrow.The aim of this study is to evaluate the efficiency and safety between NVB plus OXA (NO) regimen and NP regimen for advanced NSCLC. METHODS: We searched CBM, CNKI, VIP, Cochrane Library, PubMed, EMBASE, ASCO etc.conference proceedings and internet information.Randomized controlled trials of NO versus NP for advanced NSCLC were included; we evaluated the quality of the included studies and analyzed data by Cochrane Collaboration's RevMan 5.0 software. RESULTS: Fourteen randomized trials involving 1 270 patients were included.There were no statistical differences between NO and NP in overall response rate, disease control rate, 1-year survival rate, anemia and thrombocytopenia.Gastrointestinal toxicity, leucopenia, alopecia and kidney toxicity were more serious in NP (P < 0.05), but neuritis was more serious in NO, with significant difference (P < 0.05). CONCLUSION: The clinical efficacy of NO and NP for advanced NSCLC was similar, but the side effects were different.The toxicity of NO has the tendency to be more tolerable.